WO2011022727A3 - Antibodies against the ectodomain of erbb3 and uses thereof - Google Patents

Antibodies against the ectodomain of erbb3 and uses thereof Download PDF

Info

Publication number
WO2011022727A3
WO2011022727A3 PCT/US2010/046364 US2010046364W WO2011022727A3 WO 2011022727 A3 WO2011022727 A3 WO 2011022727A3 US 2010046364 W US2010046364 W US 2010046364W WO 2011022727 A3 WO2011022727 A3 WO 2011022727A3
Authority
WO
WIPO (PCT)
Prior art keywords
erbb3
antibodies
receptor
antigen binding
binding fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/046364
Other languages
French (fr)
Other versions
WO2011022727A2 (en
Inventor
Birgit Schoeberl
Ulrik Nielsen
Michael Feldhaus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merrimack Pharmaceuticals Inc
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011022727(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EA201200195A priority Critical patent/EA201200195A1/en
Priority to IN1518DEN2012 priority patent/IN2012DN01518A/en
Priority to CN2010800477186A priority patent/CN103002912A/en
Priority to SG2012011664A priority patent/SG178509A1/en
Priority to CA2771744A priority patent/CA2771744A1/en
Priority to KR1020127007280A priority patent/KR20120059568A/en
Priority to BR112012003809A priority patent/BR112012003809A2/en
Priority to AU2010284018A priority patent/AU2010284018C1/en
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Priority to EP10810721A priority patent/EP2467164A2/en
Priority to JP2012525756A priority patent/JP5752687B2/en
Priority to MX2012002172A priority patent/MX336091B/en
Publication of WO2011022727A2 publication Critical patent/WO2011022727A2/en
Priority to TNP2012000057A priority patent/TN2012000057A1/en
Priority to IL218097A priority patent/IL218097A0/en
Priority to ZA2012/01195A priority patent/ZA201201195B/en
Anticipated expiration legal-status Critical
Priority to MA34684A priority patent/MA33582B1/en
Publication of WO2011022727A3 publication Critical patent/WO2011022727A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3.
PCT/US2010/046364 2009-08-21 2010-08-23 Antibodies against the ectodomain of erbb3 and uses thereof Ceased WO2011022727A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
JP2012525756A JP5752687B2 (en) 2009-08-21 2010-08-23 Antibodies against ectodomain of ERBB3 and use thereof
IN1518DEN2012 IN2012DN01518A (en) 2009-08-21 2010-08-23
CN2010800477186A CN103002912A (en) 2009-08-21 2010-08-23 Antibodies against the extracellular domain of ErbB3 and uses thereof
SG2012011664A SG178509A1 (en) 2009-08-21 2010-08-23 Antibodies against the ectodomain of erbb3 and uses thereof
CA2771744A CA2771744A1 (en) 2009-08-21 2010-08-23 Antibodies against the ectodomain of erbb3 and uses thereof
KR1020127007280A KR20120059568A (en) 2009-08-21 2010-08-23 Antibodies against the ectodomain of erbb3 and uses thereof
BR112012003809A BR112012003809A2 (en) 2009-08-21 2010-08-23 isolated monoclonal antibody or antigen binding portion thereof, composition and method for treating cancer in an individual.
AU2010284018A AU2010284018C1 (en) 2009-08-21 2010-08-23 Antibodies against the ectodomain of ErbB3 and uses thereof
EP10810721A EP2467164A2 (en) 2009-08-21 2010-08-23 Antibodies against the ectodomain of erbb3 and uses thereof
EA201200195A EA201200195A1 (en) 2009-08-21 2010-08-23 ANTIBODIES AGAINST EKTODOMENA ErbB3 AND THEIR APPLICATION
MX2012002172A MX336091B (en) 2009-08-21 2010-08-23 Antibodies against the ectodomain of erbb3 and uses thereof.
TNP2012000057A TN2012000057A1 (en) 2009-08-21 2012-02-09 Antibodies against the ectodomain of erbb3 and uses thereof
IL218097A IL218097A0 (en) 2009-08-21 2012-02-14 Antibodies against the ectodomain of erbb3 and uses thereof
ZA2012/01195A ZA201201195B (en) 2009-08-21 2012-02-17 Antibodies against the ectodomain of erbb3 and uses thereof
MA34684A MA33582B1 (en) 2009-08-21 2012-03-12 ANTIBODIES AGAINST ERBB3 ECTODOMAINE AND USES THEREOF

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23579909P 2009-08-21 2009-08-21
US61/235,799 2009-08-21

Publications (2)

Publication Number Publication Date
WO2011022727A2 WO2011022727A2 (en) 2011-02-24
WO2011022727A3 true WO2011022727A3 (en) 2013-06-27

Family

ID=43607614

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/046364 Ceased WO2011022727A2 (en) 2009-08-21 2010-08-23 Antibodies against the ectodomain of erbb3 and uses thereof

Country Status (21)

Country Link
EP (1) EP2467164A2 (en)
JP (1) JP5752687B2 (en)
KR (1) KR20120059568A (en)
CN (1) CN103002912A (en)
AU (1) AU2010284018C1 (en)
BR (1) BR112012003809A2 (en)
CA (1) CA2771744A1 (en)
CR (1) CR20120108A (en)
DO (1) DOP2012000044A (en)
EA (1) EA201200195A1 (en)
EC (1) ECSP12011740A (en)
IL (1) IL218097A0 (en)
IN (1) IN2012DN01518A (en)
MA (1) MA33582B1 (en)
MX (1) MX336091B (en)
NI (1) NI201200027A (en)
PE (1) PE20121585A1 (en)
SG (1) SG178509A1 (en)
TN (1) TN2012000057A1 (en)
WO (1) WO2011022727A2 (en)
ZA (1) ZA201201195B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
BR112012012160B1 (en) 2009-11-13 2022-04-26 Amgen, Inc. Material and methods to treat or prevent diseases associated with her-3
PH12012501157A1 (en) 2009-12-22 2012-10-29 Roche Glycart Ag Anti-her3 antibodies and uses thereof
KR101798679B1 (en) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
US8481687B2 (en) 2010-04-09 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-ErbB3 antibodies
SG187908A1 (en) 2010-08-20 2013-03-28 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding protein
IT1402149B1 (en) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma USE OF A PHOSPHOPEPTIDE WHICH IS ABLE TO BLOCK THE HER3 / P85 INTERACTION FOR THE TREATMENT OF HER2 EXPRESSION TUMORS.
KR101862832B1 (en) 2010-11-01 2018-05-30 심포젠 에이/에스 Pan-her antibody composition
BR112013027021A2 (en) 2011-04-19 2016-11-29 Merrimack Pharmaceuticals Inc monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
KR20140033152A (en) * 2011-06-20 2014-03-17 교와 핫꼬 기린 가부시키가이샤 Anti-erbb3 antibody
PH12014500483A1 (en) 2011-09-30 2014-04-14 Regeneron Pharma Anti-erbb3 antibodies and uses thereof
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
AU2012318541B2 (en) 2011-10-06 2018-04-12 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
JP6149042B2 (en) * 2011-11-09 2017-06-14 ザ ユーエービー リサーチ ファンデーション HER3 antibody and use thereof
KR102083957B1 (en) 2011-12-05 2020-03-04 노파르티스 아게 Antibodies for epidermal growth factor receptor 3 (her3)
US20150037336A1 (en) * 2012-02-22 2015-02-05 U3 Pharma Gmbh Combination of hb-egf binding protein and egfr inhibitor
AR094403A1 (en) 2013-01-11 2015-07-29 Hoffmann La Roche ANTI-HER3 ANTIBODY COMBINATION THERAPY
WO2015058108A1 (en) * 2013-10-17 2015-04-23 Sanford-Burnham Medical Research Institute Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
CN110642952B (en) * 2014-08-14 2021-05-25 上海生物制品研究所有限责任公司 anti-HER 3 antibody, preparation method and application thereof
WO2016038609A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
WO2016038610A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017069628A2 (en) 2015-10-23 2017-04-27 Merus N.V. Binding molecules that inhibit cancer growth
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
US12195551B2 (en) 2017-05-17 2025-01-14 Merus N.V. Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
SI3665198T1 (en) 2017-08-09 2025-06-30 Merus N.V. Antibodies that bind egfr and cmet
US11390686B2 (en) 2017-08-09 2022-07-19 University Of Saskatchewan HER3 binding agents and uses thereof
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
JP2021534811A (en) * 2018-06-22 2021-12-16 シーアールディー ファーマシューティカルズ インコーポレイティド Anti-HER3 antibody and its uses
CN122011191A (en) * 2020-10-14 2026-05-12 苏州盛迪亚生物医药有限公司 Anti-HER 3 antibody and anti-HER 3 antibody drug conjugate and medical application thereof
KR20230128271A (en) * 2020-11-20 2023-09-04 악티늄 파마슈티컬즈, 인코포레이티드 HER3 radioimmunotherapy for the treatment of solid cancers
IL309337A (en) * 2021-06-15 2024-02-01 Beijing Sinotau Bio Pharmaceuticals Tech Co Ltd Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof
WO2023198138A1 (en) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 Antibody or antigen-binding fragment thereof and medical use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008100624A2 (en) * 2007-02-16 2008-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008100624A2 (en) * 2007-02-16 2008-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BES CEDRIC ET AL: "Mapping the paratope of anti-CD4 recombinant Fab 13B8.2 by combining parallel peptide synthesis and site-directed mutagenesis.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 16, 18 April 2003 (2003-04-18), pages 14265 - 14273, XP009168603, ISSN: 0021-9258 *
BURENKOVA OLGA ET AL: "In vivo effect of combination therapy. An anti ErbB3 antibody, MM121, plus selected cancer therapies", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 50, April 2009 (2009-04-01), & 100TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; DENVER, CA, USA; APRIL 18 -22, 2009, pages 298, XP009168595, ISSN: 0197-016X *
FONTAYNE ALEXANDRE ET AL: "Paratope and epitope mapping of the antithrombotic antibody 6B4 in complex with platelet glycoprotein Ib alpha", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 282, no. 32, August 2007 (2007-08-01), pages 23517 - 23524, XP009168604, ISSN: 0021-9258 *
GUDDAT L W ET AL: "Three-dimensional structure of human immunoglobulin with a hinge deletion", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 90, 1 May 1993 (1993-05-01), pages 4271 - 4275, XP003005005, ISSN: 0027-8424, DOI: 10.1073/PNAS.90.9.4271 *
HEINEMANN V ET AL: "Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR", CANCER TREATMENT REVIEWS, SAUNDERS, US, vol. 35, no. 3, 1 May 2009 (2009-05-01), pages 262 - 271, XP026041609, ISSN: 0305-7372, [retrieved on 20081230], DOI: 10.1016/J.CTRV.2008.11.005 *
KARPUSAS M ET AL: "Crystal Structure of the alpha1beta1 Integrin I Domain in Complex with an Antibody Fab Fragment", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 327, no. 5, 11 April 2003 (2003-04-11), pages 1031 - 1041, XP027101422, ISSN: 0022-2836, [retrieved on 20030411], DOI: 10.1016/S0022-2836(03)00203-1 *
LAMORIL J ET AL: "KRAS et cancer colorectal : un pas de geant vers la medecine personnalisee", IMMUNO ANALYSE ET BIOLOGIE SPECIALISE, ED. SCIENTIFIQUES ELSEVIER, PARIS, FR, vol. 24, no. 4, 1 August 2009 (2009-08-01), pages 196 - 209, XP026669816, ISSN: 0923-2532, [retrieved on 20090903], DOI: 10.1016/J.IMMBIO.2009.05.001 *
LEE J W ET AL: "ERBB2 kinase domain mutation in the lung squamous cell carcinoma", CANCER LETTERS, NEW YORK, NY, US, vol. 237, no. 1, 8 June 2006 (2006-06-08), pages 89 - 94, XP027883618, ISSN: 0304-3835, [retrieved on 20060608] *
SCHOEBERL B ET AL: "Therapeutically targeting ErbB3: A key node in ligand-induced activation of the ErbB receptor-PI3K axis", SCIENCE SIGNALING, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 2, no. 77 ra 31, 30 June 2009 (2009-06-30), pages 1 - 14, XP008143326, ISSN: 1945-0877, DOI: 10.1126/SCISIGNAL.20003521945- *
YAMAMOTO H ET AL: "Impact of EGFR mutation analysis in non-small cell lung cancer", LUNG CANCER, ELSEVIER, AMSTERDAM, NL, vol. 63, no. 3, 1 March 2009 (2009-03-01), pages 315 - 321, XP025910371, ISSN: 0169-5002, [retrieved on 20080829], DOI: 10.1016/J.LUNGCAN.2008.06.021 *

Also Published As

Publication number Publication date
AU2010284018B2 (en) 2014-06-05
IL218097A0 (en) 2012-04-30
WO2011022727A2 (en) 2011-02-24
MA33582B1 (en) 2012-09-01
ECSP12011740A (en) 2013-02-28
EA201200195A1 (en) 2012-12-28
CN103002912A (en) 2013-03-27
DOP2012000044A (en) 2012-06-30
MX2012002172A (en) 2012-05-29
NI201200027A (en) 2013-01-29
AU2010284018A1 (en) 2012-03-22
AU2010284018C1 (en) 2015-10-15
KR20120059568A (en) 2012-06-08
BR112012003809A2 (en) 2019-09-24
JP5752687B2 (en) 2015-07-22
ZA201201195B (en) 2015-07-29
TN2012000057A1 (en) 2013-09-19
EP2467164A2 (en) 2012-06-27
CR20120108A (en) 2012-06-05
MX336091B (en) 2016-01-08
CA2771744A1 (en) 2011-02-24
JP2013506622A (en) 2013-02-28
IN2012DN01518A (en) 2015-06-05
SG178509A1 (en) 2012-04-27
PE20121585A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
TN2012000057A1 (en) Antibodies against the ectodomain of erbb3 and uses thereof
MX2009008656A (en) Antibodies against erbb3 and uses thereof.
PH12019501115A1 (en) Anti-cd134 (ox40) antibodies and uses thereof
AU2018253639A1 (en) Compositions and methods for antibodies targeting EPO
WO2014059442A3 (en) Antibody based reagents that specifically recognize toxic oligomeric forms of tau
WO2014083208A9 (en) Binding proteins comprising at least two repeat domains against her2
WO2012058592A3 (en) Non-antagonistic egfr-binding molecules and immunoconjugates thereof
WO2011130603A3 (en) Anti-vla-4 antibodies
WO2011123785A3 (en) Frizzled-binding agents and uses thereof
WO2012019024A3 (en) Her3-binding molecules and immunoconjugates thereof
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
MY181648A (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
WO2012088302A3 (en) Half immunoglobulin binding proteins and uses thereof
WO2012085069A3 (en) Detection of a polypeptide dimer by a bivalent binding agent
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
IN2014CN04373A (en)
PH12015500751A1 (en) Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4
EP3656788A3 (en) Improved anti-serum albumin binding variants
NZ724395A (en) Anti-pdgf-c antibodies
WO2015048008A3 (en) Binding molecules specific for her3 and uses thereof
WO2012072731A3 (en) Improved anti-serum albumin binding single variable domains
CA3036643C (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
WO2012022734A3 (en) Anti-icam-1 antibodies and methods of use
WO2012022703A3 (en) Improved anti-serum albumin binding variants
HK1166273A (en) Antibodies against the ectodomain of erbb3 and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10810721

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 218097

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 0150512

Country of ref document: KE

WWE Wipo information: entry into national phase

Ref document number: 1518/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2012525756

Country of ref document: JP

Ref document number: 000234-2012

Country of ref document: PE

Ref document number: MX/A/2012/002172

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2012000444

Country of ref document: CL

Ref document number: 1201000689

Country of ref document: TH

Ref document number: 2771744

Country of ref document: CA

Ref document number: 12012500356

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 12032939

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2010284018

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 201200195

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: CR2012-000108

Country of ref document: CR

REEP Request for entry into the european phase

Ref document number: 2010810721

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010810721

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: DZP2012000191

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 20127007280

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201202009

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2010284018

Country of ref document: AU

Date of ref document: 20100823

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: CR2012-000108

Country of ref document: CR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012003807

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012003809

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012003809

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120217